REVIEW

Dynamics of Patient-Based Benefit-Risk Assessment of Medicines in Chronic Diseases: A Systematic Review

Hiba EL Masri [ID][1], Treasure M McGuire [ID][1−3], Mieke L van Driel [ID][4], Helen Benham [ID][5,6], Samantha A Hollingworth [ID][1]

[1]School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia; [2]Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland, Australia; [3]Mater Pharmacy, Mater Health, Brisbane, Queensland, Australia; [4]Primary Care Clinical Unit, Faculty of Medicine, The University of Queensland, Brisbane, Australia; [5]Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia; [6]Department of Rheumatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia

Correspondence: Hiba EL Masri, School of Pharmacy, The University of Queensland, 20 Cornwall St, Woolloongabba, Brisbane, Queensland, 4102, Australia, Tel +61 478512234, Email h.elmasri@uqconnect.edu.au

Background: A critical gap exits in understanding the dynamics of patient-based benefit-risk assessment (BRA) of medicines in chronic diseases during the disease journey.

Purpose: To systematically review and synthesize current evidence on the changes of patients' preferences about the benefits and risks of medicines during their disease journey including the influence of disease duration and severity, and previous treatment experience.

Methods: A systematic review of studies identified in PubMed and Embase, from inception to November 2020, was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. Articles were eligible if they analyzed adult patient-based BRA of medicines with a chronic disease, based on at least one of the pre-specified dimensions: disease severity, disease duration, or previous treatment experience.

Results: A total of 26,228 articles were identified and 105 were eligible for inclusion. Of these, 85 detected a variation in patient-based BRA of medicines with at least one of the pre-specified criteria. Patients with higher disease severity and more treatment experience have increased risk tolerance. It remains inconclusive whether disease duration directly affects the relative importance of a patient's preference.

Conclusion: Factors important for patients' BRA of their medicines during a chronic disease journey vary more with their clinical situation and previous treatment experience than with time since diagnosis. Due to the importance of these factors on patients' perspectives and potential impact on their decision-making and eventually their clinical outcomes, there is a need for more studies to assess the dynamics of patients' BRA in every disease.

Keywords: patient preference, choice behavior, decision making, health knowledge, attitudes, practice, attributes, risk tolerance

Introduction

Benefit-risk assessment of medicines (BRA) is primarily an exercise that balances two dimensions: the dimension of benefit which includes not only therapeutic efficacy but also improvement of quality of life, and the dimension of risk which consists of the safety profile of the given medicine and the potential risk of unobserved adverse events anticipated on the basis of the mechanism of action and mode of administration.[1] The dimension of cost is also often embedded in this analysis.[2] BRA of medicines – based on current evidence – is regularly performed at multiple levels to ensure the judicious and safe use of medicines: at a macro-level in regulatory decisions, at a meso-level in guidelines setting, and at a micro-level in shared-decision making.[3] Often, however, expert assessment fails to incorporate patients' preferences and perceptions that might be incongruous with clinicians' presumptions and opinions.[4] A patient-based BRA can

complement the expert evidence-based analysis and therefore enhance patients' involvement, satisfaction, and ultimately adherence, and clinical outcomes. The concept of a more patient-focused evaluation of medicines has emerged and has gained increasing attention from experts and researchers in the last decade.[5]

Patient-based BRA of medicines is commonly associated with sociodemographic characteristics[6,7] but it is unclear if an individual's patient-based BRA changes during disease progression. Evidence shows that patients tend to evaluate the benefits and risks of their medicines on a shorter time scale than medical professionals.[8] However, they may continue to revise their initial BRA and expectations as a result of eventual iterative trial and evaluation, experiences with unwanted side effects, and improvement or worsening of their condition. Increasing numbers of consecutive treatments and a longer disease duration result in an "experienced patient" and in the setting of a chronic disease this may well influence treatment preferences and benefit risk trade-offs.[9]

Little is known about the dynamics of patient-based BRA of medicines during chronic disease journeys. We therefore aim to systematically review current evidence on the changes of patients' preferences about the benefits and risks of their medicines during their disease journey, specifically with longer disease duration, increased disease severity, and treatment experience.

Methods

We developed a protocol for our review (PROSPERO ID: CRD42020190966) and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[10]

Systematic Literature Search

We performed a systematic search using PubMed and EMBASE databases from inception to 30 November 2020 using a validated generic search strategy to retrieve published data on patient-based BRA of medicines,[11] in combination with search terms relevant to chronic diseases and corresponding treatments. We provided the search syntaxes used in PubMed and EMBASE in Supplementary Information 1. We included studies if they analyzed perceptions or preferences of adult patients (>18 years) with a chronic disease about the balance of benefits and risks of their treatment based on stage of the disease, treatment history, other clinical characteristics, or time post-diagnosis. Chronic diseases, also known as noncommunicable diseases, tend to be long lasting conditions with persistent effects.[12,13] They are generally the result of a combination of genetic, physiological, environmental and behavioral factors.[12] The most reported chronic conditions groups include arthritis, asthma, back pain, cancer, cardiovascular disease, chronic obstructive pulmonary disease, diabetes, chronic kidney disease, mental health conditions and osteoporosis.[13]

We excluded studies if they predominately discussed adherence, failed to address patients' perceptions or preferences on the benefits and risks of chronic treatment, addressed public perceptions or preferences on the benefits and risks of preventive treatment, or did not have a sub-group analysis of patient preferences based on at least on one of three pre-specified dimensions: disease severity, disease duration and previous treatment experience. We chose these dimensions as indicators of disease progression in chronic conditions. In fact, long-standing disease duration is a hallmark of chronic conditions.[12] Moreover, adapting therapeutic strategies based on disease severity and previous lines of treatment is an overarching principle in the management of chronic diseases.

Data Extraction

Two reviewers (HM and SH) fully reviewed and independently assessed studies for inclusion and extracted data into a spreadsheet. We resolved disagreements by discussion and adjudication with a third reviewer. For each article that met our inclusion criteria, the two reviewers independently extracted the data. We collected information relevant to the STROBE checklist[14] and specifically included: authors, year of publication, study country, disease or condition, sample size, target study population plus age and gender, methods used to elicit patient preferences, attributes assessed, and summary of findings.

Quality Assessment

There are no established criteria to assess risk of bias or the methodological quality of patient preference studies[15] but some reviewers have adapted existing quality assessment models used for randomized clinical trials or constructed a new

tool.[16,17] We adopted a checklist constructed by Eiring et al[17] consisting of 31 quality criteria within five domains: 1) external validity of the study, 2) quality of construct representation, 3) minimization of the risk of construct-irrelevant variance due to multiple factors such as impairments in the cognitive abilities of the participants, numeracy skills, emotions and prejudices, 4) quality of reporting and analysis, and 5) other aspects that may strengthen or weaken the study. Two reviewers (HM and SH) independently scored all studies and categorized them into high, medium, and low overall quality, with disagreements resolved by consensus (Supplementary Information 2, Table S1).

Data Synthesis and Analysis

A meta-analysis was not appropriate because the included studies would be methodologically and clinically diverse. Therefore, we qualitatively synthesized the results and presented them in narrative and tabular forms to clarify the nature of changes patient-based BRA of medicines with longer disease duration, increased disease severity, and more patient treatment experience. We used our findings to develop a model of the interrelationships and dynamics of patient-based BRA of medicines in chronic disease.

Results

The search returned 26,228 records and we removed 955 duplicate records (using automatic deduplication in Endnote followed by a manual process). We screened the 25,273 remaining articles at title and abstract level; 544 articles were assessed for inclusion. After full text review, 105 eligible articles were included (Figure 1).

Figure 1 Flowchart of literature search results.

Study Characteristics

These articles assessed the variation of patient-based BRA of medicines with at least one of three pre-defined criteria for this systematic review: disease duration, disease severity, and treatment experience. Most articles (n = 78, 74%) investigated the variation of patient-based BRA of medicines with one of these dimensions, 26 articles (25%) investigated the variation of patient preferences with two dimensions; only one article (1%) examined all three (Table 1). Four in five studies (n = 85, 81%) detected a variation in patient-based BRA of medicines with at least one of the three pre-specified dimensions. There was no association between any of the three dimensions and patient preferences of medicines attributes in 20 studies (19%).

Most articles (n = 79, 75%) were published between 2010 and 2020, a quarter (n = 25, 24%) between 2000 and 2009, and one article (1%) was published before 2000. Predominately, the studies were conducted in one country (n = 87, 83%), with the majority from North America and Europe. There was a wide range of therapeutic areas, including autoimmune, cardiovascular, and gastrointestinal diseases, diabetes, and cancer (Table 1). All studies conducted their analyses at a specific point of time of the chronic condition, and there were no studies taking multiple BRA measures over an extended period.

68% (n = 71) of studies were of medium quality, 24% (n = 25) were high, and 8% (n = 9) were of low quality (Supplementary Information 1). High-quality studies typically had a detailed and efficient process to construct attributes and levels, as well as a high effort to minimize the risk of irrelevant variance, by piloting the study or sequencing the questions. 95% of studies were rated high in the quality of reporting and analysis, particularly for the analysis of pre-specified measures and patients' subgroups.

The number of participants in the included studies varied between 11 and 14,033 and two-thirds of the studies (n = 66, 63%) had between 101 and 500 participants with eight studies (7%) including more than 1000 participants (Table 1). Participants were predominantly female with 35 studies having less than 50% female participants. In most studies (94%) the targeted population were outpatients; only three studies had a mixed cohort of inpatients and outpatients, and three studies did not report these details. There were many recruitment approaches and settings, and some studies adopted more than one approach to achieve the targeted sample size and ensure a representative group of patients. The approaches encompassed recruitment via patient and consumer panels, research agencies, patient registries and databases, patient societies and local groups, and in clinics, specialty centres, and hospitals. Almost half of the studies (n = 50, 48%) reported the response rate, which varied between 7% and 100%.

All studies included a well-defined study question and conducted pre-specified analyses; 22 studies (21%) combined two or more methodologies (Table 1). The analyses were predominantly quantitative; only two studies were qualitative and eight had a mixed method approach. The strategies to elicit patient preferences for their treatment attributes included: discrete choice experiment, other conjoint analysis method, standard gamble, time trade-off, willingness to pay, best-worst scenario, survey or questionnaire, interview, and other methods. The attributes most frequently investigated were outcome-related attributes (n = 98, 93%), mainly efficacy and safety, as well as process-related attributes (n = 68, 65%), including mode of administration and frequency and timing of dosage. Cost-related attributes were assessed in 34 studies (32%).

Disease Duration

Twenty-three studies (22% of total included studies) addressed the variation of patient-based BRA of medicines with disease duration (Table 2): 8 studies (35% of subset) found that with a longer disease duration, patients tend to accept a higher risk of potential side effects and/or higher cost in trade of higher efficacy whereas three studies (13% of subset) reported the opposite. Twelve studies (52% of subset) did not detect any variation in patient preferences with disease duration.

Disease Severity

Fifty-one studies (49% of total included studies) measured the impact of disease severity on patient-based BRA of medicines (Table 3). Overall, 29 studies (57% of subset) reported patients were more willing to accept a higher risk of treatment-related side effects or a higher cost of treatment when they had more severe symptoms, more disease damage, or a higher risk for disease progression. Thirteen studies (25% of subset) reported a greater risk aversion and a reduced importance for efficacy with disease progression whilst the reminder (n = 9, 17% of subset) found no variation of patient-based BRA with disease severity.

Table 1 Description of Studies Included in the Systematic Review

Aspect and Categories	n
Year of publication	
Before 2000	1
Between 2000 and 2009	25
Between 2010 and November 2020	79
Number of participants	
≤100	14
101–500	66
501–1000	17
>1000	8
Females in the study population (%)	
<50%	35
50–75%	38
>75%	32
Response rate (%)	
<25%	5
25–49%	10
50–74%	16
≥75%	19
Not reported	55
Analysis approach	
Quantitative analysis	95
Qualitative analysis	2
Mixed-methods approach	8
Methods used for patient preferences elicitation	
Discrete choice experiment	47
Conjoint analysis (other than discrete choice experiment)	18
Standard gamble	5
Time trade-off	6
Willingness-to-pay	10
Best-worst scenario	3
Toxicity trade-off	1
Probability discounting	1
Threshold questions	1
Decision-making questionnaire	1
Multicriteria decision analysis	1
Maximum difference scaling	1
Rating scale	1
Forced ranking	1
Survey or questionnaire	27
Interview	7
Focus group	1
Attributes studied	
Outcome-related attributes	98
Efficacy	90
Safety	92
Quality of life	9
Process-related attributes	68
Mode of administration	47

(*Continued*)

Table 1 (Continued).

Aspect and Categories	n
Frequency and timing of dosage	52
Device-related and storage properties	8
Waiting time for medicine administration	4
Location of administration	15
Cost-related attributes	34

Table 2 Studies Assessing the Variations of Patient-Based BRA of Medicines with Disease Duration

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Patients accepting higher risk or cost with longer disease duration					
Aristides et al 2004[30]	France, Germany, Italy, Spain, and the United Kingdom	Discrete choice conjoint analysis Recruitment by a research agency	290	Type 2 Diabetes mellitus	The longer a patient had had diabetes, the greater the willingness to pay for treatment
Arroyo et al 2017[31]	Spain	Conjoint analysis Recruitment by treating neurologists	221	Relapsing-remitting multiple sclerosis	Patients with a recent diagnosis (<1 year) had the highest importance assigned to side effect risk
Bauer et al 2020[32]	Australia, Canada, Germany, Switzerland and the United States	Discrete choice exercise Recruitment through local patient groups	485	Relapsing-remitting multiple sclerosis	Patients diagnosed <10 years ago were more concerned about the safety profile of the therapy, while patients diagnosed ≥10 years ago place most importance on treatment efficacy
Garcia-Dominguez et al 2016[33]	Spain	Discrete choice experiment Recruitment by patient associations	125	Multiple sclerosis	Patients with shorter disease duration (less than 5 years) were significantly less concerned about preventing progression than those with 5 or more years since diagnosis, and more concerned about treatment side effects
Johnson et al 2007[34]	The United States	Conjoint analysis Recruitment by an online panel and from clinical practice sites	580	Crohn's disease	Patients who have been diagnosed for more years are willing to accept a higher risk of serious adverse events
Kromer et al 2015[35]	Germany	Conjoint analysis Recruitment from clinic	200	Psoriasis	With longer disease duration, sustainability of efficacy became increasingly more important for patients
Meads et al 2017[36]	The United Kingdom	Discrete choice experiment, willingness-to-pay Recruitment from care centers	221	Pain management in cancer	Patients with longer disease period were more averse to severe pain than those with a more recent diagnosis, and required more efficacy from treatment

(*Continued*)

Table 2 (Continued).

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Morillas et al 2015[37]	Spain and Portugal	Discrete choice experiment, willingness-to-pay Recruitment from hospitals and clinics	330	Type 2 diabetes mellitus	Patients with longer disease duration put more importance on outcomes rather than convenience
Schaarschmidt et al 2011[38]	Germany	Conjoint analysis Recruitment from a university medical center	163	Psoriasis	Patients with longer disease duration attached significantly greater importance to duration of benefit and less importance on side effects than those with shorter disease duration
Patients accepting less risk or cost with longer disease duration					
Manjunath et al 2012[39]	The United States	Discrete choice experiment/conjoint analysis Recruitment from a patient panel	193	Epilepsy	Patients with a longer history of epilepsy were less likely to accept an add-on antiepileptic agent
O'Brien et al 1990[40]	The United Kingdom	Questionnaire/ Standard gamble Recruitment from a specialized hospital	100	Rheumatic diseases	Patients who had been diseased for a greater number of years had less willingness to accept risk associated with treatment
Schaarschmidt et al 2018[41]	Germany	Discrete choice experiment Recruitment in dermatology centres and via a patient organisation	222	Psoriasis	With increasing disease duration, patients put less importance on efficacy and more importance on safety
No variation of patient preferences with disease duration					
Bottomley et al 2017[18]	The United Kingdom	Discrete choice experiment Recruitment by a medical recruitment agency	350	Multiple sclerosis	No significant differences in preferences found in sub-group analysis based on time since diagnosis
Bruce et al 2018[19]	The United States	Questionnaire/ Probability discounting Recruitment from a specialty clinic and via a specialized patient newsletter	225	Relapsing-remitting multiple sclerosis	Discounting of efficacy or side effects did not significantly differ with diagnosis duration
Choi et al 2008[20]	The United States	Interview Recruitment from a clinic	52	Asthma	No differences found in patients' perception of benefits or drawbacks of medicines according to disease duration
Fraenkel et al 2001[21]	The United States	Adaptive conjoint analysis Recruitment in community practices	103	Lupus nephritis	No associations found between disease duration with patients' preferences
Gelhorn et al 2019[22]	The United States	Discrete choice experiment/ Interview Recruitment from clinical sites	47	Severe asthma	Treatment preferences were similar regardless of years since diagnosis

(*Continued*)

Table 2 (Continued).

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Johnson et al 2009[23]	The United States	Discrete stated choice survey Recruitment from multiple patient panels	651	Multiple sclerosis	Maximum acceptable risk for serious adverse effects did not change with years of diagnosis
Lewis et al 2020[24]	The United Kingdom, The United States, and Germany	Discrete choice experiment Recruitment via recruitment agencies, patients support groups, and patient key opinion leaders	450	Chronic obstructive pulmonary disease	The time since diagnosis did not change the relative importance patients had put on their medicines' attributes
Rigopoulos et al 2017[25]	Greece	Discrete choice experiment Recruitment from clinics	310	Psoriasis	Duration of the disease had no influence on patients' treatment preferences
Scarpato et al 2010[26]	Italy	Questionnaire Recruitment from rheumatology centers	822	Rheumatoid arthritis	Patients' preferences for route of administration were not influenced by disease duration
Tada et al 2019[27]	Japan	Discrete choice experiment Recruitment via a patient panel	395	Psoriasis	Disease duration had no impact on patients' preferences
Turk et al 2020[28]	The United States	Discrete choice experiment/ Best-worst scenario Recruitment via patient panels	602	Osteoarthritis pain or chronic low back pain	No significant differences found in patients' preferences based on time living with chronic pain
Wong et al 2013[29]	The United States	Discrete choice experiment Recruitment from a cancer center and a community hospital	400	Cancer	No association found between years of diagnosis and patient preferences

Table 3 Studies Assessing the Variations of Patient-Based BRA of Medicines with Disease Severity

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Patients accepting higher risk or cost with higher disease severity					
Alcusky et al 2017[42]	The United States	Discrete choice experiment Recruitment from consumer and patient panels	196	Psoriasis	With more severe symptoms, patients put more importance on efficacy.
Athavale et al 2018[43]	The United States	Discrete choice experiment Recruitment from an independent respondent panel	514	Treatment-naïve overactive bladder	Respondents with nocturia put higher relative importance for treatments that reduced nocturia

(Continued)

Table 3 (Continued).

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Brooks et al 2019[44]	Japan	Discrete choice experiment Recruitment by a patient recruitment organization	161	Type 2 Diabetes mellitus	Patients with a higher HbA1c placed more significance on efficacy and HbA1c change
Bruce et al 2018[45]	The United States	Questionnaire Recruitment from a clinic, via letters, and via advertisements online and in a specialized patient newsletter	290	Multiple sclerosis	Patients with more progressive disease reported increased willingness to take medications when confronted with possible severe side effects.
Chapman et al 2014[46]	The United Kingdom	Questionnaire Recruitment from general practices	398	Epilepsy	Patients with more seizures have more positive perceptions about their medicines
de Bekker et al 2008[47]	The Netherlands	Discrete choice experiment/ Trade-off Recruitment from general practices	120	Osteoporosis	High-risk patients accepted a less effective drug to reduce their fracture risk
Fayad et al 2008[48]	Lebanon	Survey Recruitment by treating physicians in clinics and hospitals	693	Rheumatoid arthritis	Radiographic damage was associated with a significant change in patients' preferences
Fox et al 2015[49]	The United States	Standard gamble Recruitment from an online registry	5446	Multiple sclerosis	Patients with an increased disability level had higher risk acceptance to therapies
Fraenkel et al 2010[50]	The United States	Adaptive conjoint analysis Recruitment from clinics	140	Hepatitis C	Patients with higher severity of liver disease placed higher importance on benefits and less importance on risk of toxicity from therapy
Fraenkel et al 2007[51]	The United States	Adaptive conjoint analysis Recruitment from centers	185	Osteoporosis	Preference for injectable treatments was stronger among women with a relatively higher perceived risk of fracture
Fu et al 2016[52]	The United States	Standard gamble Recruitment from a cancer center	107	Metastatic colorectal cancer	Patients at stage IV had greater willingness to tolerate treatment related adverse events than those at stage III
Gallagher et al 2003[53]	The United States	Questionnaire Recruitment via a patient panel	2444	Migraine	Patients reporting more severe headaches preferred treatment with higher speed of onset whereas patients with milder headaches preferred treatment with no side effects

(*Continued*)

Table 3 (Continued).

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Gray et al 2009[54]	Canada	Rating survey Recruitment via a patient panel	100	Ulcerative colitis	Patients experiencing disease flare put more importance on speed of symptom relief and less importance on side effects
Hauber et al 2017[55]	The United States	Discrete choice experiment Recruitment via a patient panel and a patient association	599	Chronic hand eczema	Patients with limitations on daily activities due to severe eczema had higher maximum acceptable risk of adverse events estimates
Hauber et al 2009[56]	The United Kingdom and The United States	Discrete choice experiment Recruitment via an online panel	407	Type II diabetes mellitus	Patients with glycated haemoglobin above 7.5% placed more importance on benefits, including heart-attack risk and glucose control
Hiligsmann et al 2017[57]	Belgium, France, Ireland, the Netherlands, Spain, Switzerland and the United Kingdom	Discrete choice experiment Recruitment by mail	1124	Osteoporosis	Patients with previous fractures put more importance on drug effectiveness, and are willing to pay more for medication than those without previous fractures
Hodgkins et al 2012[58]	The United States, The United Kingdom, Canada, and Germany	Discrete choice experiment Recruitment by local independent patient recruitment services	400	Ulcerative colitis	Patients who experienced more recent flares had a greater preference for treatments that reduced flare risk
Howell et al 2017[59]	Australia	Best-worst scaling Recruitment from transplant units and via an online patient panel	93	Immunosuppression after kidney transplantation	Having had more than 1 transplant and increasing comorbidities were both associated with greater concern for long graft survival
Johnson et al 2010[60]	The United States	Discrete stated choice survey Recruitment via an online panel	576	Irritable bowel syndrome	Patients with more severe symptoms had higher maximum acceptable risk for side effects than patients who had less severe symptoms
Kløjgaard et al 2014[61]	Denmark	Discrete choice experiment Recruitment from a public center	348	Low back pain	Patients with higher score on the pain scale were less risk-averse than those with lower pain scores
Lacy et al 2015[62]	The United States	Standard gamble Recruitment via mail using a data reporting system	114	Functional dyspepsia	Patients with severe and/or mixed symptoms were willing to take more risks with a hypothetical medication
Lim et al 2019[63]	The United States	Survey Recruitment from a patient registry and clinics	676	Systemic lupus erythematosus	Patients with disease damage had less concern of complications from treatment than those with no disease damage

(Continued)

Table 3 (Continued).

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Manjunath et al 2012[39]	The United States	Discrete choice experiment/conjoint analysis Recruitment from a patient panel	193	Epilepsy	Patients with no seizures in 3 last months were less likely to accept an add-on antiepileptic agent
Mantovani et al 2005[64]	Italy	Discrete choice experiment Recruitment from centers	178	Hemophilia	Patients with severe haemophilia had less concern about viral safety than those with moderate haemophilia
Meads et al 2017[36]	The United Kingdom	Discrete choice experiment, willingness-to-pay Recruitment from care centers	221	Pain management in cancer	Patients with poor pain relief were less willing to wait for treatment
Nolla et al 2016[65]	Spain	Conjoint analysis Recruitment from hospitals	488	Rheumatic diseases	Patients with more severe disease symptoms put higher importance on pain relief and improvement in functional capacity
O'Brien et al 1990[40]	The United Kingdom	Questionnaire/ Standard gamble Recruitment from a specialized hospital	100	Rheumatic diseases	Patients' willingness to accept risk increases with reductions in self-assessed health status
Ratcliffe et al 2004[66]	The United Kingdom	Conjoint analysis Recruitment by phone calls via a market research database	412	Osteoarthritis	Patients with more severe symptoms put higher importance on pain reduction and lower importance on risk of serious side-effects than those with mild symptoms
Schaarschmidt et al 2018[41]	Germany	Discrete choice experiment Recruitment in dermatology centers and via a patient organization	222	Psoriasis	With increasing disease severity, patients had less concern regarding serious side effects
Patients accepting less risk or cost with higher disease severity					
Hehir et al 2020[104]	The United States	Survey Recruitment via a patient society	283	Myasthenia gravis	Patients treated with medications that could indicate more severe disease manifestation had more concern regarding potential adverse events
Johnson et al 2007[34]	The United States	Conjoint analysis Recruitment by an online panel and from clinical practice sites	580	Crohn's disease	Patients with more severe symptoms were less tolerant of serious adverse events risks than those with less severe symptoms

(*Continued*)

Table 3 (Continued).

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Kaehler et al 2016[122]	Germany	Standard gamble/ Threshold questions Recruitment from skin cancer centers	130	Melanoma	Patients with pre-existing cancer had considerably higher threshold benefits for the chance of being melanoma-free at 5 years than those without any antecedent malignancy
Kuchuk et al 2013[123]	Canada	Standard gamble Recruitment from cancer centers	69	Breast cancer	Patients with advanced disease placed less importance on survival benefit and higher importance on quality of life
Lee et al 2016[124]	Korea	Discrete choice experiment/ trade-off/ Willingness-to-pay Recruitment in a cancer center	102	Advanced ovarian cancer	Patients without experience of recurrence were more likely to choose additional treatment and higher cost than those with experience of recurrence
Lewis et al 2020[24]	The United Kingdom, The United States, and Germany	Discrete choice experiment Recruitment via recruitment agencies, patients support groups, and patient key opinion leaders	450	Chronic obstructive pulmonary disease	Patients who had experienced more exacerbations in the past put less importance on treatment efficacy in decreasing exacerbations in the next year
Lloyd et al 2005[125]	The United Kingdom	Discrete choice experiment/ Willingness-to-pay Recruitment via a patient society	148	Epilepsy	Patients with higher seizure frequency had a lower willingness-to-pay for seizure control than those with lower seizure frequency
Marchesini et al 2019[92]	Italy	Discrete choice experiment Recruitment from outpatient centers	662	Type 2 diabetes mellitus	Patients with higher body mass index put more importance on avoidance of risk of weight gain
Merlino et al 2001[126]	The United States	Rating scale/ Time trade-off Recruitment from a university clinic	107	Rheumatoid arthritis	Patients who experienced a prior fracture had a higher preference to avoid potential fracture as a potential glucocorticoid-associated adverse event
Osilla et al 2011[127]	The United States	Questionnaire Recruitment from HIV clinics	127	Hepatitis C and HIV coinfection	Patients with lower CD4 counts had a lower acceptance for additional hepatitis C treatment
Poulos et al 2016[128]	The United States	Discrete choice experiment Recruitment by an online patient panel	192	Multiple sclerosis	Patients with mild symptoms placed greater weight on decreasing the number of relapses than those with moderate or worse symptoms

(*Continued*)

Table 3 (Continued).

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Tada et al 2019[27]	Japan	Discrete choice experiment Recruitment via a patient panel	395	Psoriasis	Patients with lower disease severity gave more importance on sustained efficacy
Utz et al 2014[129]	Germany	Conjoint analysis Recruitment from a hospital department	156	Relapsing remitting multiple sclerosis	Patients with higher disability scores were more likely to prefer pills over injections
No variation of patient preferences with disease severity					
Bottomley et al 2017[18]	The United Kingdom	Discrete choice experiment Recruitment by a medical recruitment agency	350	Multiple sclerosis	No significant differences in preferences found in sub-group analyses based on disease severity
Bröckelmann et al 2019[67]	France, Germany, and The United Kingdom	Discrete choice experiment Recruitment from a research database	381	Hodgkin lymphoma	Patient preference for progression free survival over overall survival was observed regardless of the stage of disease, early or intermediate/ advanced
Choi et al 2008[20]	The United States	Interview Recruitment from a clinic	52	Asthma	No differences found in patients' perception of benefits or drawbacks of medicines according to disease severity
Gajra et al 2018[68]	The United States	Trade-off approach Recruitment of a subset of patients included in a randomised trial	145	Breast cancer	Preferences for chemotherapy were not associated with hormone receptor status, performance status, or tumour and nodal stage
Havrilesky et al 2014[69]	The United States	Discrete choice experiment/ Ranking and rating approaches Recruitment from a clinic	95	Ovarian cancer	Similar preferences between patients with disease recurrence and those without
Hendriks et al 2018[70]	Columbia	Best-worst scaling Recruitment from clinics	195	Human immune deficiency virus	No difference in preferences for treatment characteristics between patients with symptoms and those with no symptoms
Jarmolowicz et al 2017[71]	The United States	Decision-making questionnaire Recruitment from a specialty clinic	42	Relapsing remitting multiple sclerosis	Patients with higher disability score did not have different decisions when weighing benefits and side effects of their medicines
Johnson et al 2009[23]	The United States	Discrete stated choice survey Recruitment from multiple patient panels	651	Multiple sclerosis	Maximum acceptable risk for serious adverse effects did not change with, disability score, the number of relapses per year, or current multiple sclerosis category

(*Continued*)

Table 3 (Continued).

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Wong et al 2013[29]	The United States	Discrete choice experiment Recruitment from a cancer center and a community hospital	400	Cancer	No association found between presence of metastases with patient preferences

Treatment Experience

Fifty-eight studies (55% of total included studies) examined the dynamics of the evolution of patient-based BRA of medicines with previous treatment experiences (Table 4): 37 studies (64% of subset) reported an increased patient acceptance of risks, cost, or inconvenience with treatment experience, 10 studies (17% of subset) reported a decreased

Table 4 Studies Assessing the Variations of Patient-Based BRA of Medicines with Treatment Experience

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Patients accepting higher risk or cost with treatment experience					
Arroyo et al 2017[31]	Spain	Conjoint analysis Recruitment by treating neurologists	221	Relapsing remitting multiple sclerosis	Patients having previously received more than one disease-modifying therapy gave a higher importance to relapse rate reduction than patients receiving their first therapy
Bauer et al 2020[32]	Australia, Canada, Germany, Switzerland, and The United States	Discrete choice exercise Recruitment through local patient groups	485	Relapsing remitting multiple sclerosis	For those currently on injectable therapy, the administration route and dosing frequency were significantly less important compared with patients on oral therapy
Berry et al 2004[72]	The United Kingdom	Questionnaire Recruitment from a clinic	81	Rheumatoid arthritis and other painful musculoskeletal conditions	Treated patients had a greater perception of the effectiveness of treatment than those newly diagnosed
Beusterien et al 2007[73]	The United States and Germany	Conjoint survey Recruitment through advertisements in newspapers, in clinics, and via non-profit patient support centers	288	Human immunodeficiency virus	Treatment-experienced patients perceived the risk of severe rash to be less important than treatment-naïve patients

(Continued)

Table 4 (Continued).

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Blinman et al 2016[74]	Australia and New Zealand	Time trade-off questionnaire Recruitment from sites participating in a study	83	Endometrial cancer	Patients who had adjuvant chemotherapy judged smaller benefits sufficient to accept therapy
Bruce et al 2018[45]	The United States	Questionnaire Recruitment from a clinic, via letters, and via advertisements online and in a specialized patient newsletter	290	Multiple sclerosis	Patients who had never taken a disease-modifying therapy reported less willingness to take one
Casciano et al 2011[75]	Algeria, Egypt, Iran, Lebanon, Morocco, Tunisia, Saudi Arabia, the United Arab Emirates, China, Malaysia, Thailand, Turkey, Argentina, Chile, Colombia, Guatemala, Mexico and Venezuela	Discrete choice modelling Recruitment from an international registry	14,033	Diabetes mellitus	Insulin-treated patients placed less importance on mode of administration (oral vs injection) than insulin-naïve patients
Cefalu et al 2008[76]	The United States, The United Kingdom, France, Germany, Spain, Mexico, and Brazil	Survey Recruitment from an international online patient database and via physicians	1444	Type 2 diabetes mellitus	Insulin-naive respondents were more averse to taking subcutaneous insulin in the future
Desplats et al 2017[77]	France	Questionnaire Recruitment from rheumatology departments of tertiary care hospitals	201	Rheumatoid arthritis	Patients who had another ongoing subcutaneous treatment preferred to switch from intravenous to subcutaneous, whereas patients only receiving intravenous treatment preferred not to switch
Dowson et al 2007[78]	The United Kingdom	Patient preference questionnaire Recruitment from a clinic	48	Migraine	With treatment experience, patients preferred the newer formulations more than conventional oral tablets
Duarte et al 2007[79]	France, Germany, Mexico, Spain, and The United Kingdom	Cross-sectional survey Recruitment through participating physicians and door-to-door by a designated interviewer	3000	Osteoporosis	Higher percentages of untreated participants than treated participants ranked side effects and out-of-pocket expenses as the most important attributes

(*Continued*)

Table 4 (Continued).

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Eliasson et al 2017[80]	The United Kingdom	Discrete choice experiment Recruitment via an online patient panel	292	Psoriasis	Participants with no prior exposure to biologic therapies were more averse to the risks of treatment toxicities compared with people with biologic exposure and biologic-experienced cohort was more willing to accept injection treatments
Emkey et al 2005[81]	The United States	Preference questionnaire Recruitment from centers	342	Osteoporosis	Treatment-naïve patients put more importance on convenience of treatment than experienced patients
Engelhard et al 2016[82]	Netherlands	Survey Recruitment via a patient monitoring society	958	Human immunodeficiency virus	With more treatment experience, patients put less importance on convenience of treatment
Fayad et al 2018[48]	Lebanon	Survey Recruitment by treating physicians in clinics and hospitals	693	Rheumatoid arthritis	Patients who experienced side effects from previous treatments had a higher preference for oral administration over subcutaneous or intravenous
Flood et al 2017[83]	The United States	Adaptive conjoint analysis survey Recruitment via a market research panel	167	Diabetes mellitus	Insulin-experienced and injection-experienced subgroups put less importance on regimen and mode of administration
Garcia-Dominguez et al 2016[33]	Spain	Discrete choice experiment Recruitment by patient associations	125	Multiple sclerosis	Treatment-naïve patients are more risk averse, put less importance on efficacy and more importance on route and frequency of administration
Grisanti et al 2019[84]	The United States and Canada	Survey Recruitment from clinical practices included in a larger study	1841	Rheumatologic diseases	Higher percentage of biologic-naïve patients overall expressed preference for intravenous therapy than for subcutaneous therapy than biologic-experienced patients
Ho et al 2020[85]	Australia	Discrete choice experiment Recruitment via consumer groups and an online consumer panel	206	Inflammatory arthritis	Biologic-experienced patients were more likely to accept injection and infusion treatments than biologic-naïve patients

(Continued)

Table 4 (Continued).

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Huynh et al 2014[86]	Denmark	Survey Recruitment from university clinics	142	Rheumatoid arthritis	Biologic-naïve and biologic-experienced patients using subcutaneous injections preferred subcutaneous injections over infusion, whereas biologic-experienced on infusion still preferred intravenous administration at the clinic over self-injections
Johansson et al 2004[87]	Sweden	Conjoint analysis questionnaire Recruitment from centers	298	Asthma	Patients on different treatments expressed variant preferences for attributes of alternative treatment
Kowacs et al 2009[88]	Brazil	Rating questionnaire Recruitment from clinics	203	Migraine	Patients overusing antimigraine medicines accepted having greater degrees of possible adverse events than those patients who did not overuse antimigraine drugs
Kromer et al 2015[35]	Germany	Conjoint analysis Recruitment from clinic	200	Psoriasis	Patients with more experience with systemic agents favoured sustainability of benefits
Lim et al 2013[89]	Singapore	Questionnaire Recruitment from a clinic	421	Hepatitis B	Treatment-experienced patients were willing to pay more for a higher efficacy than treatment-naïve patients
Lloyd et al 2011[90]	The United Kingdom	Discrete choice experiment/ Willingness-to-pay Recruitment in clinics and via advertisement in newspapers	485	Diabetes mellitus	Patients with previous experiences of hypoglycaemia as a side effect had a higher tolerance for this potential side effect and less willingness-to-pay to avoid it
Mansfield et al 2017[91]	Germany and Spain	Discrete choice experiment Recruitment from local communities and an online consumer panel	875	Type 2 diabetes mellitus	Patients with experience in injectable treatments put more importance on the efficacy of the medicine and less importance on the mode or frequency of administration
Marchesini et al 2019[92]	Italy	Discrete choice experiment Recruitment from outpatient centers	662	Type 2 diabetes mellitus	Previous experience with self-injectables strengthens patients' willingness to accept injectable drugs

(*Continued*)

Table 4 (Continued).

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
McTaggart-Cowan et al 2008[93]	Canada	Discrete choice experiment/ Willingness-to-pay Recruitment by a poster advertisement in a research clinic	157	Asthma	Patients using higher amounts of short-acting β -agonists had a greater preference for a treatment that resulted in more monthly symptom-free days
Morillas et al 2015[37]	Spain and Portugal	Discrete choice experiment, willingness-to-pay Recruitment from hospitals and clinics	330	Type 2 diabetes mellitus	Patients receiving injectable treatment placed less importance on convenience attributes
Peyrot et al 2011[94]	The United States	Survey Recruitment by an online patient panel	1094	Type 2 diabetes mellitus	Patients taking only oral treatment had a higher interest in using inhaled insulin if available and avoiding injectables
Schaarschmidt et al 2011[38]	Germany	Conjoint analysis Recruitment from a university medical center	163	Psoriasis	Patients on injectables attach great importance to efficiency
van Heuckelum et al 2019[95]	The Netherlands	Discrete choice experiment Recruitment from rheumatology departments	325	Rheumatoid arthritis	Patients on injectable biologics put less importance on oral administration
Verhoef et al 2018[96]	The Netherlands	Maximum difference scaling/Interview Recruitment in a hospital rheumatology department and via electronic patient records	214	Rheumatoid arthritis	Patients with previous experience in dose reduction were more reluctant to de-escalate their current treatment
Vigneau et al 2019[97]	France	Discrete choice experiment Recruitment in clinics	789	Anemia in chronic kidney disease	With increasing experience with injectable treatments, patients put less importance on convenience such as frequency of injections
Weilandt et al 2020[98]	Germany	Discrete choice experiment Recruitment from dermatology centers	150	Advanced melanoma	Patients who had been treated with immune checkpoint inhibitors regarded overall response rate as more important than did others and had less concern regarding immune related adverse events

(Continued)

Table 4 (Continued).

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Weiss et al 2006[99]	The United States	Forced ranking/ Survey Recruitment from a pool of respondents to national surveys	999	Osteoporosis	Treated patients placed more importance on effectiveness whereas untreated patients had a higher concern regarding side effects
Wong et al 2020[100]	Singapore	Discrete choice experiment Recruitment from a cancer center	169	Metastatic colorectal cancer	Patients naïve to chemotherapy placed more importance on avoiding severe side effects
Patients accepting lower risk or cost with treatment experience					
Blinman et al 2018[101]	Australia and New Zealand, and The United Kingdom	Validated preferences questionnaire Recruitment from trial sites	233	Renal cell carcinoma	Participants who experienced side-effects required larger benefits to warrant adjuvant therapy
Brotherston et al 2013[102]	Canada	Toxicity trade-off/ Semi-structured interviews Recruitment in a cancer clinic	51	Oropharyngeal cancer	Patients who underwent more than three cycles of chemotherapy were less willing to trade certainty of survival with avoiding toxicity than those treated with less cycles
Hardtstock et al 2020[103]	Germany	Discrete choice experiment Recruitment from multiple gastroenterology and hepatology centers	108	Chronic hepatitis B	Patients who experienced previous side-effects put more importance on safety profile than efficacy or route of administration
Hehir et al 2020[104]	The United States	Survey Recruitment via a patient society	283	Myasthenia gravis	Patients who experienced previous side-effects put more importance on safety profile than efficacy or route of administration
Islam et al 2019[105]	The United States	Ranking questionnaire Recruitment from cancer centers	232	Lung cancer	With more experience with chemotherapy, patients had tolerability for side effects decreased
Locadia et al 2006[106]	The Netherlands	Survey/ Interview Recruitment from clinics	136	HIV	Patients with more extensive experience with highly active antiretroviral therapy had a preference for a later initiation of therapy

(*Continued*)

Table 4 (Continued).

| Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Mantovani et al 2005[64]	Italy	Discrete choice experiment Recruitment from centers	178	Hemophilia	The effect of viral safety was greater for patients taking recombinant treatment
Pacou et al 2015[130]	The United Kingdom	Discrete choice experiment Recruitment from a patient panel	100	Hepatitis C	Patients currently receiving treatment put more importance on efficacy than those who already terminated their treatment course
Postmus et al 2018[107]	The United Kingdom	Multicriteria decision analysis Recruitment via a cancer charity	560	Multiple myeloma	Patients who had previously experienced severe or life-threatening side effects attached a higher weight to mild or moderate chronic toxicity than to progression-free survival
Poulos et al 2019[108]	The United States	Discrete choice experiment Recruitment by a patient association and a patient panel	250	Endometriosis	Patients who experienced moderate to severe hot flashes accepted less risk of increased hot flashes
No variation of patient preferences with treatment experience					
Chancellor et al 2012[131]	France, Germany, Italy, Spain, Sweden, and The United Kingdom	Discrete choice experiment/focus group Recruitment from international panels	242	Chronic pain	No association found between variation in treatment history and preferences for attributes of opioids
daCosta DiBonaventura et al 2014[132]	The United States	Conjoint analysis Recruitment from cancer-specific online panels	181	Breast cancer	Patient preferences did not vary with treatment experience
Das et al 2014[133]	The United Kingdom	Semi-structured interviews Recruitment by an early intervention team	11	Psychotic illnesses	No association found between patients' perceptions on antipsychotic long-acting injections and previous treatment
Fraenkel et al 2018[134]	The United States, Puerto Rico	Conjoint analysis Recruitment via a patient network, social media, respondent panel providers, and research companies	1273	Rheumatoid arthritis	No association found between current biologic use and patient preferences

(Continued)

Table 4 (Continued).

Reference, Year of Publication	Countries	Study Design and Recruitment of Participants	Sample Size	Disease or Condition	Summary Results
Fraenkel et al 2001[21]	The United States	Adaptive conjoint analysis Recruitment in community practices	103	Lupus nephritis	No associations found between treatment history and patients' preferences
Gelhorn et al 2019[22]	The United States	Discrete choice experiment/ Interview Recruitment from clinical sites	47	Severe asthma	Treatment preferences were similar regardless of treatment status (corticosteroid or biologic)
Havrilesky et al 2014[69]	The United States	Discrete choice experiment/ Ranking and rating approaches Recruitment from a clinic	95	Ovarian cancer	Similar preferences found between patients currently receiving and those not receiving chemotherapy
Husni et al 2017[135]	The United States	Discrete choice experiment/ Willingness-to-pay/ Willingness-to-trade Recruitment from a patient panel	510	Rheumatoid arthritis	Biologic-naïve patients had similar benefit-risk ratios and preferences for attributes to those who are biologic-experienced
Lewis et al 2020[24]	The United Kingdom, The United States, and Germany	Discrete choice experiment Recruitment via recruitment agencies, patients support groups, and patient key opinion leaders	450	Chronic obstructive pulmonary disease	Previous experience with side effects did not change the relative importance patients had put on attributes
Poulos et al 2016[128]	The United States	Discrete choice experiment Recruitment by an online patient panel	192	Multiple sclerosis	No differences in preferences found between treatment naïve and treatment experienced patients
Turk et al 2020[28]	The United States	Discrete choice experiment/ Best-worst scenario Recruitment via patient panels	602	Osteoarthritis pain or chronic low back pain	No significant differences in patients' preferences based on previous treatment experience

Abbreviations: BRA, benefit-risk assessment; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology statement; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

patient tolerance of risks, cost, or inconvenience with treatment history while 11 studies (19% of subset) found no association.

Narrative Synthesis

Our findings suggest that patient preferences may not have a clear association with disease duration. Half of the studies addressing the variation of patient-based BRA of medicines with disease duration (52%) reported no association between risk acceptance and disease duration,[18–29] with fewer studies (35%) reported a higher tolerance for risk with more years

Figure 2 Inter-relationship model of the dynamics of patient-based BRA of medicines in chronic disease.

since diagnosis[30–38] whilst 13% reporting the opposite with more risk aversion with longer disease duration.[39–41] There is a clearer association between patient preferences and disease severity with more than half of the studies (57%) identified in this category reported an increased risk tolerance with progressing disease severity[36,39–66] whilst 17% of these studies found no association.[18,20,23,29,67–71] There was a discernable association between patient treatment experience and increased risk tolerance (64%).[31–33,35,37,38,45,48,72–100] Efficacy-related attributes as well as willingness-to-pay for more efficacious treatment gained more importance for patients with increasing experience with medicines.[33,35,45,72,74,79,89,93,96,99] Safety-related attributes had more weight for treatment-naïve patients, but the importance diminished for patients with more treatment experience as they became more risk-tolerant.[33,73,79,80,88,90,98–100] Process-related attributes, and particularly acceptance of injectable medications, changed considerably with treatment experience. Patients with more exposure to treatment were less concerned about the convenience of treatment and more open to using different formulations and routes of administration.[33,78,81,82,87] Patients who had used injectable medicines placed less importance on mode of administration and convenience and were more willing to accept self-injectable treatments than patients who had not used these prior.[32,37,38,75–77,80,83–86,91,92,94,95,97] However, not expectantly, previous experience of side effects was associated with patients becoming more risk averse.[64,101–108] A model depicting the inter-relationship and dynamic impact of disease severity, disease duration and treatment experience on patients' preferences and risk tolerance in chronic disease is represented in Figure 2.

Discussion

We identified 105 studies that investigated patient preferences of medicines' attributes in a vast range of chronic conditions and explored preferences across three dimensions of disease duration, disease severity, and treatment experience. Most studies (81%) reported variations in patient preferences with one or more dimensions and only 19% found no association. The findings suggest that patient treatment experience, positive or negative, and disease severity are dominant factors that influence the dynamics of patient-based BRA of medicines. Disease duration seems to be a weaker contributor to these dynamics. In fact, time since diagnosis, when considered as an independent direct factor, provides increasing opportunities of preference reinforcement. However, in chronic disease, it is most often that with time patients

may experience worsening of symptoms, more lines of treatments, and side effects.[107] This may suggest that disease duration also provides circular reinforcement of the dominant factors influencing the dynamics of patient preferences.

Patients have an increasing risk tolerance and a greater willingness-to-pay with treatment experience during their disease journey.[31–33,35,37,38,45,48,72–100] This may be explained by the impact of previous treatments on patients' preferences.[109] Although treatment-naïve patients are relatively more risk averse than treatment-experienced patients,[79,99,100] the latter who had previously endured side effects become less risk tolerant.[101,103,107,108] This is in line with the concept distinguishing patients' perceptions ex-ante (prior to an event/anticipated) and ex-post (after the event/experienced),[110] when a direct experience of a serious adverse event may alter how patients assess the BRA of their medicines. They may overemphasize risk and overestimate the severity of potential side effects.[111] For example, patients with multiple myeloma who had previously experienced severe or life-threatening side effects put more importance on low toxicity than on progression-free survival.[107]

Another salient result is the increased acceptance of injectable treatments, notably self-administration, among patients who had already used this mode of administration. For example, insulin-naive patients are more averse to taking subcutaneous insulin in the future[76] whereas insulin-treated patients placed less importance on mode of administration.[75] Abu Hassan et al found that negative concerns about the use of insulin such as self-injection, needle phobia, inconvenience, and embarrassment are significantly higher in insulin-naïve diabetic patients than in experienced insulin-user diabetic patients.[112] This is confirmed by the increased use of subcutaneous injectable devices, driven by increased users' satisfaction with respect to convenience, ergonomics, and portability.[113]

Moreover, we found that patients with higher disease severity,[42,50,52] more pronounced symptoms,[46] or increased disease damage[49] placed higher importance on efficacy and less importance on the safety profile and cost. Indeed, patients may tolerate more severe potential side effects when their disease progression negatively affects their quality of life. For example, patients with inflammatory bowel disease develop a greater acceptance for potential risks of treatment when their condition worsens, in a desperate search for a cure.[114] It remains inconclusive how disease duration, as an independent factor, alters patient preferences. The contrast across these dimensions suggests that factors important for patients' assessment of benefits and risks of their medicines during a chronic disease journey will vary more with their clinical situation and previous treatment experience than with time since their diagnosis.

The studies revealed a range of strategies to elicit patient preferences. Conjoint analysis methods (especially discrete choice experiments) were the most frequently used, but there were 15 different methods employed in the studies reviewed. This mirrors the overall upward trend observed in the use of patient preferences elicitation methods over the last decade.[115] There is currently no comprehensive comparison of these emerging methods, but increasing publications are providing guidance to select the most appropriate approach for a given application.[116–118]

What are the implications for discussing benefits and risks of medicines with patients, at different points along their disease journey? Treatment paradigms and recommendations are shifting to earlier and more aggressive treatments. For example, in rheumatoid arthritis there is a "window of opportunity" in the first three months of disease onset to prevent damage occurring.[119] Our results suggest that patients will be more risk averse and concerned during this phase, although they will become more risk tolerant and put higher importance on efficacy with more experience with treatment or when their symptoms become more severe. It is critical that patients and clinicians adequately understand that individual BRA may change.

Understanding the dynamics of patient-based BRA is also important when considering patient preferences in regulatory decisions. Having patients directly involved in the decision-making process or using evidence derived from patients in empirical studies should be routinely utilised as part of the evidence considered.[4,120] Such input must be balanced and derived from cohorts of patients at different points of their disease journey and with different levels of exposure to treatments.

Despite the current evidence of the dynamics of patient-based BRA of medicines during the disease journey, only 105 out of 544 identified in the title and abstract screening had sub-group analyses based on disease duration, disease severity, or treatment experience. Due to the importance of these dimensions on patient preferences and potential impact on patients' decision-making and clinical outcomes, there is a need for more studies to assess changes: larger studies that may be statistically powered for such sub-group analyses; the use of different methodologies; or longitudinal studies.

Strengths and Limitations

This is the first study, to our knowledge, to systematically review evidence of the dynamics of patient-based BRA of medicines in chronic diseases. The strengths of our review include the registered protocol, a validated search strategy, pre-specified eligibility criteria, and duplicate screening and data extraction.

This review has several limitations. Given the methodological and clinical heterogeneity of included studies, it was not possible to draw robust conclusions or conduct a meta-analysis. Therefore, we considered a narrative synthesis to be the most suitable format. We note that such a review is subject to a higher bias than a quantitative systematic review.[121] However, the strong and consistent trends across the varied methods and wide range of chronic diseases studied support our proposed dynamic BRA model.

This review encompassed studies from various chronic conditions, with substantial differences in the burden of the disease on the patients as well as the efficacy-safety profile of suggested treatments. Moreover, studies included were not longitudinal. They assessed patients' BRA of their medicines at one point of their disease journey when there may be other unidentified individual factors impacting patients' perspectives.

Conclusion

This study identified and reviewed a large body of literature regarding the dynamics of patient-based BRA of medicines during the disease journey in chronic conditions. We conclude that factors impacting patients' risk tolerance vary more with their disease severity and previous treatment experience than with time since diagnosis. These findings may be utilized to provide context for patient centered clinical decision-making around the use of medicines in chronic disease.

Key Points for Decision Makers

- Patient assessment of benefits and risks of medicines in chronic conditions is likely to evolve during the disease journey
- Patients with increased treatment experience tend to become more risk tolerant
- Patients with experience in self-injectables have a higher acceptance for this mode of administration
- Patients with increased disease severity are willing to accept higher risks to achieve improved clinical outcomes
- Patients with experiences of side effects may become more risk averse

Acknowledgments

Author Contributions

All authors made a significant contribution to the review reported, whether that is in the conception, design, execution, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Curtin F, Schulz P. Assessing the benefit: risk ratio of a drug–randomized and naturalistic evidence. *Dialogues Clin Neurosci*. 2011;13(2):183–190. doi:10.31887/DCNS.2011.13.2/fcurtin
2. Eichler HG, Abadie E, Raine JM, et al. Safe drugs and the cost of good intentions. *N Engl J Med*. 2009;360(14):1378–1380. doi:10.1056/NEJMp0900092
3. Muhlbacher AC, Juhnke C. Patient preferences versus physicians' judgement: does it make a difference in healthcare decision making? *Appl Health Econ Health Policy*. 2013;11(3):163–180. doi:10.1007/s40258-013-0023-3

4. Muhlbacher AC, Juhnke C, Beyer AR, et al. Patient-focused benefit-risk analysis to inform regulatory decisions: the European Union perspective. *Value Health*. 2016;19(6):734–740. doi:10.1016/j.jval.2016.04.006

5. van Til JA, Ijzerman MJ. Why should regulators consider using patient preferences in benefit-risk assessment? *Pharmacoeconomics*. 2014;32 (1):1–4. doi:10.1007/s40273-013-0118-6

6. Bewtra M, Johnson FR. Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. *Patient*. 2013;6(4):241–255. doi:10.1007/s40271-013-0031-2

7. Durand C, Eldoma M, Marshall DA, et al. Patient preferences for disease modifying anti-rheumatic drug treatment in rheumatoid arthritis: a systematic review. *J Rheumatol*. 2020;47(2):176–187. doi:10.3899/jrheum.181165

8. Dohnhammar U, Reeve J, Walley T. Patients' expectations of medicines – a review and qualitative synthesis. *Health Expect*. 2016;19 (2):179–193. doi:10.1111/hex.12345

9. Kromer C, Peitsch WK, Herr R, et al. Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability. *JDDG*. 2017;15(2):189–200.

10. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097

11. El Masri H, McGuire T, Dalais C, et al. Patient-based benefit-risk assessment of medicines: development, refinement, and validation of a content search strategy to retrieve relevant studies. *J Med Libr Assoc*. 2022;110(2):185–204. doi:10.5195/jmla.2022.1306

12. World Health Organization. Noncommunicable diseases; 2021. Available from: https://www.who.int/en/news-room/fact-sheets/detail/noncommunicable-diseases. Accessed July 21, 2022.

13. Australian Institute of Health and Welfare. Chronic disease; 2021. Available from: https://www.aihw.gov.au/reports-data/health-conditions-disability-deaths/chronic-disease/overview. Accessed July 21, 2022.

14. von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLoS Med*. 2007;4(10):e296. doi:10.1371/journal.pmed.0040296

15. Yu T, Enkh-Amgalan N, Zorigt G. Methods to perform systematic reviews of patient preferences: a literature survey. *BMC Med Res Methodol*. 2017;17(1):166. doi:10.1186/s12874-017-0448-8

16. Purnell TS, Joy S, Little E, et al. Patient preferences for noninsulin diabetes medications: a systematic review. *Diabetes Care*. 2014;37 (7):2055–2062. doi:10.2337/dc13-2527

17. Eiring Ø, Landmark BF, Aas E, et al. What matters to patients? A systematic review of preferences for medication-associated outcomes in mental disorders. *BMJ Open*. 2015;5(4):e007848. doi:10.1136/bmjopen-2015-007848

18. Bottomley C, Lloyd A, Bennett G, et al. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis. *J Med Econ*. 2017;20(8):863–870. doi:10.1080/13696998.2017.1336099

19. Bruce JM, Bruce AS, Lynch S, et al. Probability discounting of treatment decisions in multiple sclerosis: associations with disease knowledge, neuropsychiatric status, and adherence. *Psychopharmacology*. 2018;235(11):3303–3313. doi:10.1007/s00213-018-5037-y

20. Choi TN, Westermann H, Sayles W, et al. Beliefs about asthma medications: patients perceive both benefits and drawbacks. *J Asthma*. 2008;45 (5):409–414. doi:10.1080/02770900801971834

21. Fraenkel L, Bodardus S, Wittnik DR. Understanding patient preferences for the treatment of lupus nephritis with adaptive conjoint analysis. *Med Care*. 2001;39(11):1203–1216. doi:10.1097/00005650-200111000-00007

22. Gelhorn HL, Balantac Z, Ambrose CS, et al. Patient and physician preferences for attributes of biologic medications for severe asthma. *Patient Prefer Adherence*. 2019;13:1253–1268. doi:10.2147/PPA.S198953

23. Johnson FR, Van Houtven G, Ozdemir S, et al. Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. *J Neurol*. 2009;256(4):554–562. doi:10.1007/s00415-009-0084-2

24. Lewis HB, Schroeder M, Gunsoy NB, et al. Evaluating patient preferences of maintenance therapy for the treatment of chronic obstructive pulmonary disease: a discrete choice experiment in the UK, USA and Germany. *Int J Chron Obstruct Pulmon Dis*. 2020;15:595–604. doi:10.2147/COPD.S221980

25. Rigopoulos D, Ioannides D, Chaidemenos G, et al.. Patient preference study for different characteristics of systemic psoriasis treatments (Protimisis). *Dermatol Ther*. 2018;31(3). doi:10.1111/dth.12592

26. Scarpato S, Antivalle M, Favalli EG, et al. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). *Rheumatology*. 2010;49(2):289–294. doi:10.1093/rheumatology/kep354

27. Tada Y, Ishii K, Kimura J, et al. Patient preference for biologic treatments of psoriasis in Japan. *J Dermatol*. 2019;46(6):466–477. doi:10.1111/1346-8138.14870

28. Turk D, Boeri M, Abraham L, et al. Patient preferences for osteoarthritis pain and chronic low back pain treatments in the United States: a discrete-choice experiment. *Osteoarthritis Cartilage*. 2020;28(9):1202–1213. doi:10.1016/j.joca.2020.06.006

29. Wong YN, Egleston BL, Sachdeva K, et al. Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting. *Med Care*. 2013;51(9):838–845. doi:10.1097/MLR.0b013e31829faffd

30. Aristides M, Weston AR, FitzGerald P, et al. Patient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multicountry application of a discrete choice experiment. *Value Health*. 2004;7(4):442–454. doi:10.1111/j.1524-4733.2004.74007.x

31. Arroyo R, Sempere AP, Ruiz-Beato E, et al. Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study. *BMJ Open*. 2017;7(3):e014433. doi:10.1136/bmjopen-2016-014433

32. Bauer B, Brockmeier B, Devonshire V, et al. An international discrete choice experiment assessing patients' preferences for disease-modifying therapy attributes in multiple sclerosis. *Neurodegener Dis Manag*. 2020;10(6):369–382. doi:10.2217/nmt-2020-0034

33. Garcia-Dominguez JM, Muñoz D, Comellas M, et al. Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment. *Patient Prefer Adherence*. 2016;10:1945–1956. doi:10.2147/PPA.S114619

34. Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. *Gastroenterology*. 2007;133(3):769–779. doi:10.1053/j.gastro.2007.04.075

35. Kromer C, Schaarschmidt ML, Schmieder A, et al. Patient preferences for treatment of psoriasis with biologicals: a discrete choice experiment. *PLoS One*. 2015;10(6):e0129120. doi:10.1371/journal.pone.0129120

36. Meads DM, O'Dwyer JL, Hulme CT, et al. Patient preferences for pain management in advanced cancer: results from a discrete choice experiment. *Patient*. 2017;10(5):643–651. doi:10.1007/s40271-017-0236-x

37. Morillas C, Feliciano R, Catalina PF, et al. Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment.. *Patient Prefer Adherence*. 2015;9:1443–1458. doi:10.2147/PPA.S88022

38. Schaarschmidt ML, Umar N, Schmieder A, et al. Patient preferences for psoriasis treatments: impact of treatment experience. *J Eur Acad Dermatol Venereol*. 2013;27(2):187–198. doi:10.1111/j.1468-3083.2011.04440.x

39. Manjunath R, Yang JC, Ettinger AB. Patients' preferences for treatment outcomes of add-on antiepileptic drugs: a conjoint analysis. *Epilepsy Behav*. 2012;24(4):474–479. doi:10.1016/j.yebeh.2012.05.020

40. O'Brien BJ, Elswood J, Calin A. Willingness to accept risk in the treatment of rheumatic disease. *J Epidemiol Community Health*. 1990;44 (3):249–252. doi:10.1136/jech.44.3.249

41. Schaarschmidt ML, Herr R, Gutknecht M, et al. Patients' and physicians' preferences for systemic psoriasis treatments: a nationwide comparative discrete choice experiment (PsoCompare). *Acta Derm Venereol*. 2018;98(2):200–205. doi:10.2340/00015555-2834

42. Alcusky M, Lee S, Lau G, et al. Dermatologist and patient preferences in choosing treatments for moderate to severe psoriasis. *Dermatol Ther*. 2017;7(4):463–483. doi:10.1007/s13555-017-0205-2

43. Athavale A, Gooch K, Walker D, et al. A patient-reported, non-interventional, cross-sectional discrete choice experiment to determine treatment attribute preferences in treatment-naïve overactive bladder patients in the US. *Patient Prefer Adherence*. 2018;12:2139–2152. doi:10.2147/PPA.S178668

44. Brooks A, Langer J, Tervonen T, et al. Patient preferences for GLP-1 receptor agonist treatment of type 2 diabetes mellitus in Japan: a discrete choice experiment. *Diabetes Ther*. 2019;10(2):735–749. doi:10.1007/s13300-019-0591-9

45. Bruce JM, Jarmolowicz DP, Lynch S, et al. How patients with multiple sclerosis weigh treatment risks and benefits. *Health Psychol*. 2018;37 (7):680–690. doi:10.1037/hea0000626

46. Chapman SC, Horne R, Chater A, et al. Patients' perspectives on antiepileptic medication: relationships between beliefs about medicines and adherence among patients with epilepsy in UK primary care. *Epilepsy Behav*. 2014;31:312–320. doi:10.1016/j.yebeh.2013.10.016

47. de Bekker-Grob EW, Essink-Bot ML, Meerding WJ, et al. Patients' preferences for osteoporosis drug treatment: a discrete choice experiment. *Osteoporos Int*. 2008;19(7):1029–1037. doi:10.1007/s00198-007-0535-5

48. Fayad F, Ziade NR, Merheb G, et al. Patient preferences for rheumatoid arthritis treatments: results from the national cross-sectional LERACS study. *Patient Prefer Adherence*. 2018;12:1619–1625. doi:10.2147/PPA.S168738

49. Fox RJ, Salter A, Alster JM, et al. Risk tolerance to MS therapies: survey results from the NARCOMS registry. *Mult Scler Relat Disord*. 2015;4 (3):241–249. doi:10.1016/j.msard.2015.03.003

50. Fraenkel L, Chodkowski D, Lim J, et al. Patients' preferences for treatment of hepatitis C. *Med Decis Making*. 2010;30(1):45–57. doi:10.1177/0272989X09341588

51. Fraenkel L, Gulanski B, Wittink D. Patient willingness to take teriparatide. *Patient Educ Couns*. 2007;65(2):237–244. doi:10.1016/j.pec.2006.08.004

52. Fu AZ, Graves KD, Jensen RE, et al. Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment. *J Cancer Res Clin Oncol*. 2016;142(3):699–706. doi:10.1007/s00432-015-2073-4

53. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. *Headache*. 2003;43(1):36–43. doi:10.1046/j.1526-4610.2003.03006.x

54. Gray JR, Leung E, Scales J. Treatment of ulcerative colitis from the patient's perspective: a survey of preferences and satisfaction with therapy. *Aliment Pharmacol Ther*. 2009;29(10):1114–1120. doi:10.1111/j.1365-2036.2009.03972.x

55. Hauber AB, Mohamed AF, Gonzalez JM, et al. Benefit-risk tradeoff preferences for chronic hand eczema treatments. *J Dermatolog Treat*. 2017;28(1):40–46. doi:10.1080/09546634.2016.1177161

56. Hauber AB, Mohamed AF, Johnson FR, et al. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. *Diabet Med*. 2009;26(4):416–424. doi:10.1111/j.1464-5491.2009.02696.x

57. Hiligsmann M, Dellaert BG, Dirksen CD, et al. Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. *Rheumatology*. 2017;56(7):1167–1176. doi:10.1093/rheumatology/kex071

58. Hodgkins P, Swinburn P, Solomon D, et al. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment. *Patient*. 2012;5(1):33–44. doi:10.2165/11595390-000000000-00000

59. Howell M, Wong G, Rose J, et al. Patient preferences for outcomes after kidney transplantation: a best-worst scaling survey. *Transplantation*. 2017;101(11):2765–2773. doi:10.1097/TP.0000000000001793

60. Johnson FR, Hauber AB, Ozdemir S, et al. Quantifying women's stated benefit-risk trade-off preferences for IBS treatment outcomes. *Value Health*. 2010;13(4):418–423. doi:10.1111/j.1524-4733.2010.00694.x

61. Kløjgaard ME, Manniche C, Pedersen LB, et al. Patient preferences for treatment of low back pain-a discrete choice experiment. *Value Health*. 2014;17(4):390–396. doi:10.1016/j.jval.2014.01.005

62. Lacy BE, Yu J, Crowell MD. Medication risk-taking behavior in functional dyspepsia patients. *Clin Transl Gastroenterol*. 2015;6(1):e69. doi:10.1038/ctg.2014.18

63. Lim SS, Kan H, Pobiner BF, et al. Patient perceptions and preferences of biologic therapies in SLE. *Lupus Sci Med*. 2019;6(1):e000322. doi:10.1136/lupus-2019-000322

64. Mantovani LG, Monzini MS, Mannucci PM, et al. Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. *Haemophilia*. 2005;11(6):589–597. doi:10.1111/j.1365-2516.2005.01159.x

65. Nolla JM, Rodríguez M, Martin-Mola E, et al. Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain. *Patient Prefer Adherence*. 2016;10:1101–1113. doi:10.2147/PPA.S106311

66. Ratcliffe J, Buxton M, McGarry T, et al. Patients' preferences for characteristics associated with treatments for osteoarthritis. *Rheumatology*. 2004;43(3):337–345. doi:10.1093/rheumatology/keh038

67. Bröckelmann PJ, McMullen S, Wilson JB, et al. Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. *Br J Haematol*. 2019;184(2):202–214. doi:10.1111/bjh.15566

68. Gajra A, McCall L, Muss HB, et al. The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). *J Geriatr Oncol*. 2018;9(3):221–227. doi:10.1016/j.jgo.2018.02.003

69. Havrilesky LJ, Alvarez Secord A, Ehrisman JA, et al. Patient preferences in advanced or recurrent ovarian cancer. *Cancer*. 2014;120 (23):3651–3659. doi:10.1002/cncr.28940

70. Hendriks A, Wijnen B, van Engelen R, et al. A best-worst scaling in Colombian patients to rank the characteristics of HIV/AIDS treatment. *J Med Econ*. 2018;21(5):468–473. doi:10.1080/13696998.2018.1440401

71. Jarmolowicz DP, Bruce AS, Glusman M, et al. On how patients with multiple sclerosis weigh side effect severity and treatment efficacy when making treatment decisions. *Exp Clin Psychopharmacol*. 2017;25(6):479–484. doi:10.1037/pha0000152

72. Berry D, Bradlow A, Bersellini E. Perceptions of the risks and benefits of medicines in patients with rheumatoid arthritis and other painful musculoskeletal conditions. *Rheumatology*. 2004;43(7):901–905. doi:10.1093/rheumatology/keh196

73. Beusterien KM, Dziekan K, Schrader S, et al. Patient preferences among third agent HIV medications: a US and German perspective. *AIDS Care*. 2007;19(8):982–988. doi:10.1080/09540120701294278

74. Blinman P, Mileshkin L, Khaw P, et al. Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial. *Br J Cancer*. 2016;115(10):1179–1185. doi:10.1038/bjc.2016.323

75. Casciano R, Malangone E, Ramachandran A, et al. A quantitative assessment of patient barriers to insulin. *Int J Clin Pract*. 2011;65 (4):408–414. doi:10.1111/j.1742-1241.2010.02590.x

76. Cefalu WT, Mathieu C, Davidson J, et al. Patients' perceptions of subcutaneous insulin in the OPTIMIZE study: a multicenter follow-up study. *Diabetes Technol Ther*. 2008;10(1):25–38. doi:10.1089/dia.2008.0249

77. Desplats M, Pascart T, Jelin G, et al. Are Abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study. *Clin Rheumatol*. 2017;36(6):1395–1400. doi:10.1007/s10067-017-3587-8

78. Dowson A, Bundy M, Salt R, et al. Patient preference for triptan formulations: a prospective study with zolmitriptan. *Headache*. 2007;47 (8):1144–1151. doi:10.1111/j.1526-4610.2007.00805.x

79. Duarte JW, Bolge SC, Sen SS. An evaluation of patients' preferences for osteoporosis medications and their attributes: the PREFER-International study. *Clin Ther*. 2007;29(3):488–503. doi:10.1016/S0149-2918(07)80087-7

80. Eliasson L, Bewley AP, Mughal F, et al. Evaluation of psoriasis patients' attitudes toward benefit–risk and therapeutic trade-offs in their choice of treatments. *Patient Prefer Adherence*. 2017;11:353–362. doi:10.2147/PPA.S121838

81. Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). *Curr Med Res Opin*. 2005;21(12):1895–1903. doi:10.1185/030079905X74862

82. Engelhard EA, Smit C, Vervoort SC, et al. Patients' willingness to take multiple-tablet antiretroviral therapy regimens for treatment of HIV. *Drugs Real World Outcomes*. 2016;3(2):223–230. doi:10.1007/s40801-016-0070-9

83. Flood EM, Bell KF, de la Cruz MC, et al. Patient preferences for diabetes treatment attributes and drug classes. *Curr Med Res Opin*. 2017;33 (2):261–268. doi:10.1080/03007995.2016.1253553

84. Grisanti L, Kwiatkowski A, Dyrda P, et al. Patient perspectives on intravenous biologics for rheumatologic disease. *Arthritis Care Res*. 2019;71 (9):1234–1242. doi:10.1002/acr.23758

85. Ho KA, Acar M, Puig A, et al. What do Australian patients with inflammatory arthritis value in treatment? A discrete choice experiment. *Clin Rheumatol*. 2020;39(4):1077–1089. doi:10.1007/s10067-019-04843-4

86. Huynh TK, Ostergaard A, Egsmose C, et al. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. *Patient Prefer Adherence*. 2014;8:93–99. doi:10.2147/PPA.S55156

87. Johansson G, Ställberg B, Tornling G, et al. Asthma treatment preference study: a conjoint analysis of preferred drug treatments. *Chest*. 2004;125(3):916–923. doi:10.1378/chest.125.3.916

88. Kowacs PA, Piovesan EJ, Tepper SJ. Rejection and acceptance of possible side effects of migraine prophylactic drugs. *Headache*. 2009;49 (7):1022–1027. doi:10.1111/j.1526-4610.2009.01431.x

89. Lim SG, Aung MO, Chung SW, et al. Patient preferences for hepatitis B therapy. *Antivir Ther*. 2013;18(5):663–670. doi:10.3851/IMP2482

90. Lloyd A, Nafees B, Barnett AH, et al. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus. *Clin Ther*. 2011;33(9):1258–1267. doi:10.1016/j.clinthera.2011.07.017

91. Mansfield C, Sikirica MV, Pugh A, et al. Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. *Diabetes Ther*. 2017;8(6):1365–1378. doi:10.1007/s13300-017-0326-8

92. Marchesini G, Pasqualetti P, Anichini R, et al. Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis. *Acta Diabetol*. 2019;56(3):289–299. doi:10.1007/s00592-018-1236-6

93. McTaggart-Cowan HM, Shi P, Fitzgerald JM, et al. An evaluation of patients' willingness to trade symptom-free days for asthma-related treatment risks: a discrete choice experiment. *J Asthma*. 2008;45(8):630–638. doi:10.1080/02770900802126990

94. Peyrot M, Rubin RR. Perceived medication benefits and their association with interest in using inhaled insulin in type 2 diabetes: a model of patients' cognitive framework. *Patient Prefer Adherence*. 2011;5:255–265. doi:10.2147/PPA.S18799

95. van Heuckelum M, Mathijssen EGE, Vervloet M, et al. Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment. *Patient Prefer Adherence*. 2019;13:1199–1211. doi:10.2147/PPA.S204111

96. Verhoef LM, Selten EMH, Vriezekolk JE, et al. The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study. *Rheumatology*. 2018;57(11):1947–1955. doi:10.1093/rheumatology/key205

97. Vigneau C, Choukroun G, Isnard-Bagnis C, et al. "Doctor, can I have less frequent injection with highly efficient treatment?" A patient centered study using an electronic choice-based conjoint analysis (ePRO) to assess real world preferences regarding erythropoiesis stimulating agent to treat anaemia in chronic kidney disease (PERCEPOLIS study). *Nephrol Ther*. 2019;15(3):152–161. doi:10.1016/j.nephro.2018.11.009

98. Weilandt J, Diehl K, Schaarschmidt ML, et al. Patient preferences in adjuvant and palliative treatment of advanced melanoma: a discrete choice experiment. *Acta Derm Venereol*. 2020;100(6):1–9. doi:10.2340/00015555-3422

99. Weiss TW, Gold DT, Silverman SL, et al. An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. *Curr Med Res Opin*. 2006;22(5):949–960. doi:10.1185/030079906X104740

100. Wong XY, Lim AQJ, Shen Q, et al. Patient preferences and predicted relative uptake for targeted therapies in metastatic colorectal cancer: a discrete choice experiment. *Curr Med Res Opin*. 2020;36(10):1677–1686. doi:10.1080/03007995.2020.1790348

101. Blinman PL, Davis ID, Martin A, et al. Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile? *Ann Oncol*. 2018;29(2):370–376. doi:10.1093/annonc/mdx715

102. Brotherston DC, Poon I, Le T, et al. Patient preferences for oropharyngeal cancer treatment de-escalation. *Head Neck*. 2013;35(2):151–159. doi:10.1002/hed.22930

103. Hardtstock F, Sbarigia U, Kocaata Z, et al. Preferences of patients with chronic hepatitis B– a discrete choice experiment on the acceptability of functional cure. *Patient Prefer Adherence*. 2020;14:613–624. doi:10.2147/PPA.S238833

104. Hehir MK, Punga AR, Ciafaloni E. Myasthenia gravis patient and physician opinions about immunosuppressant reduction. *Muscle Nerve*. 2020;61(6):767–772. doi:10.1002/mus.26850

105. Islam KM, Anggondowati T, Deviany PE, et al. Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer. *BMC Cancer*. 2019;19(1):835. doi:10.1186/s12885-019-6054-x

106. Locadia M, van Grieken RA, Prins JM, et al. Patients' preferences regarding the timing of highly active antiretroviral therapy initiation for chronic asymptomatic HIV-1 infection. *Antivir Ther*. 2006;11(3):335–341. doi:10.1177/135965350601100309

107. Postmus D, Richard S, Bere N, et al. Individual trade-offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma. *Oncologist*. 2018;23(1):44–51. doi:10.1634/theoncologist.2017-0257

108. Poulos C, Soliman AM, Renz CL, et al. Patient preferences for endometriosis pain treatments in the United States. *Value Health*. 2019;22(6):728–738. doi:10.1016/j.jval.2018.12.010

109. MacLean S, Mulla S, Akl EA, et al. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2012;141(2Suppl):e1S–e23S. doi:10.1378/chest.11-2290

110. Harrison M, Rigby D, Vass C, et al. Risk as an attribute in discrete choice experiments: a systematic review of the literature. *Patient*. 2014;7(2):151–170. doi:10.1007/s40271-014-0048-1

111. El Masri H, Hollingworth SA, van Driel M, et al. Real-world questions and concerns about disease-modifying antirheumatic drugs (DMARDs): a retrospective analysis of questions to a medicine call center. *BMC Rheumatol*. 2020;4:27. doi:10.1186/s41927-020-00126-7

112. Abu Hassan H, Tohid H, Mohd Amin R, et al. Factors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: a qualitative exploration. *BMC Fam Pract*. 2013;14:164. doi:10.1186/1471-2296-14-164

113. Ridyard CH, Dawoud DM, Tuersley LV, et al. A systematic review of patients' perspectives on the subcutaneous route of medication administration. *Patient*. 2016;9(4):281–292. doi:10.1007/s40271-015-0160-x

114. Harvey JM, Sibelli A, Chalder T, et al. Desperately seeking a cure: treatment seeking and appraisal in irritable bowel syndrome. *Br J Health Psychol*. 2018;23(3):561–579. doi:10.1111/bjhp.12304

115. Soekhai V, Whichello C, Levitan B, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. *Drug Discov Today*. 2019;24(7):1324–1331. doi:10.1016/j.drudis.2019.05.001

116. Whichello C, Levitan B, Juhaeri J, et al. Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparison. *BMC Med Inform Decis Mak*. 2020;20(1):114.

117. Kaplan RM, Crespi CM, Dahan E, et al. Comparison of rating scale, time tradeoff, and conjoint analysis methods for assessment of preferences in prostate cancer. *Med Decis Making*. 2019;39(7):816–826. doi:10.1177/0272989X19873667

118. Meara A, Crossnohere NL, Bridges JFP. Methods for measuring patient preferences: an update and future directions. *Curr Opin Rheumatol*. 2019;31(2):125–131. doi:10.1097/BOR.0000000000000587

119. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*. 2017;76(6):960–977. doi:10.1136/annrheumdis-2016-210715

120. Johnson FR, Zhou M. Patient preferences in regulatory benefit-risk assessments: a US perspective. *Value Health*. 2016;19(6):741–745. doi:10.1016/j.jval.2016.04.008

121. Reen GK, Silber E, Langdon DW. Multiple sclerosis patients' understanding and preferences for risks and benefits of disease-modifying drugs: a systematic review. *J Neurol Sci*. 2017;375:107–122. doi:10.1016/j.jns.2016.12.038

122. Kaehler KC, Blome C, Forschner A, et al. Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy. *Medicine*. 2016;95(46):e5375. doi:10.1097/MD.0000000000005375

123. Kuchuk I, Bouganim N, Beusterien K, et al. Preference weights for chemotherapy side effects from the perspective of women with breast cancer. *Breast Cancer Res Treat*. 2013;142(1):101–107. doi:10.1007/s10549-013-2727-3

124. Lee JY, Kim K, Lee YS, et al. Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy. *Gynecol Oncol*. 2016;143(3):622–627. doi:10.1016/j.ygyno.2016.10.021

125. Lloyd A, McIntosh E, Price M. The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment. *PharmacoEconomics*. 2005;23(11):1167–1181. doi:10.2165/00019053-200523110-00008

126. Merlino LA, Bagchi I, Taylor TN, et al. Preference for fractures and other glucocorticoid-associated adverse effects among rheumatoid arthritis patients. *Med Decis Making*. 2001;21(2):122–132. doi:10.1177/0272989X0102100205

127. Osilla KC, Wagner G, Garnett J, et al. Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment. *AIDS Patient Care STDS*. 2011;25(9):533–538. doi:10.1089/apc.2011.0048

128. Poulos C, Kinter E, Yang JC, et al. Patient preferences for injectable treatments for multiple sclerosis in the United States: a discrete-choice experiment. *Patient*. 2016;9(2):171–180. doi:10.1007/s40271-015-0136-x

129. Utz KS, Hoog J, Wentrup A, et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. *Ther Adv Neurol Disord*. 2014;7(6):263–275. doi:10.1177/1756285614555335

130. Pacou M, Basso F, Gore C, et al. Patient and physician preferences for the treatment of chronic hepatitis C virus infections: does the perspective matter? *Eur J Gastroenterol Hepatol*. 2015;27(9):1063–1068. doi:10.1097/MEG.0000000000000410

131. Chancellor J, Martin M, Liedgens H, et al. Stated preferences of physicians and chronic pain sufferers in the use of classic strong opioids. *Value Health*. 2012;15(1):106–117. doi:10.1016/j.jval.2011.07.002

132. daCosta DiBonaventura M, Copher R, Basurto E, et al. Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer. *Am Health Drug Benefits*. 2014;7(7):386–396.

133. Das AK, Malik A, Haddad PM. A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. *Ther Adv Psychopharmacol*. 2014;4(5):179–185. doi:10.1177/2045125314542098

134. Fraenkel L, Nowell WB, Michel G, et al. Preference phenotypes to facilitate shared decision-making in rheumatoid arthritis. *Ann Rheum Dis*. 2018;77(5):678–683. doi:10.1136/annrheumdis-2017-212407

135. Husni ME, Betts KA, Griffith J, et al. Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective. *Rheumatol Int*. 2017;37(9):1423–1434. doi:10.1007/s00296-017-3760-z